Practical considerations for empirical Bayes estimation using a pharmacokinetic/pharmacodynamic model developed from summary-level data of ustekinumab therapy in Crohn’s disease
Journal of Pharmacy and Pharmacology · 02.06.2026 · 78 (6)
DOI: 10.1093/jpp/rgag033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 13.06.2026. Verfasst von Koji Kimura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, …. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab, Models, Biological. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objectives
This study aimed to develop a pharmacokinetic/pharmacodynamic model using summary-level data (SLD-PK/PD model) for ustekinumab in Crohn’s disease and to propose practical considerations and an operating framework for empirical Bayes estimation (EBE) when individual patient data (IPD) models are unavailable.
Methods
An SLD-PK/PD model was constructed using arm-level Crohn’s Disease Activity Index (CDAI) data from phase IIb/III trials. To evaluate EBE performance, simulated IPD (simIPD) was generated using a reported IPD-PK/PD model. Pseudo-SLD was derived from simIPD to refit the SLD-PK/PD model. EBE was performed at Week 8 to predict CDAI up to Week 20. Because individual-level variability is not identifiable from SLD, uncertainty was propagated using a prespecified σ2 grid and ω2 scaling, with η-shrinkage-guided bounds. Key findings Based on the variance-range framework, patients were classified as consistently predicted remission (6.9%), consistently predicted non-remission (66.2%), or indeterminate (26.9%). Predictive accuracy varied across σ2 assumptions, demonstrating the practical impact of variance specification.
Conclusions
Although EBE using an SLD-PK/PD model is practically useful when IPD-PK/PD models are unavailable, predictions depend on variance assumptions. Therefore, σ2 and ω2 should be treated as uncertainty ranges, and decision stability should be evaluated across these ranges to ensure robust clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Evaluation of Drug Efficacy, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
- Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital, 6-2-24 Ofuna, Kamakura, Kanagawa 247-0056, Japan.
ORCID-Profile: Koji Kimura
Zitieren
APA
Kimura, K., & Yoshida, A. (2026). Practical considerations for empirical Bayes estimation using a pharmacokinetic/pharmacodynamic model developed from summary-level data of ustekinumab therapy in Crohn’s disease. Journal of Pharmacy and Pharmacology, 78(6). https://doi.org/10.1093/jpp/rgag033
Vancouver
Kimura K, Yoshida A. Practical considerations for empirical Bayes estimation using a pharmacokinetic/pharmacodynamic model developed from summary-level data of ustekinumab therapy in Crohn’s disease. Journal of Pharmacy and Pharmacology. 2026;78(6). doi:10.1093/jpp/rgag033
BibTeX
@article{Kimura2026,
author = {Kimura, Koji and Yoshida, Atsushi},
title = {Practical considerations for empirical Bayes estimation using a pharmacokinetic/pharmacodynamic model developed from summary-level data of ustekinumab therapy in Crohn’s disease},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {6},
doi = {10.1093/jpp/rgag033}
}
EUVIMED